Neuroprotection on the Horizon: Are GLP-1 Receptor Agonists the Next Breakthrough in Parkinson’s Disease?
Objective: This meta-analysis evaluates the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with Parkinson’s disease (PD). Background: Epidemiological studies suggest an increased…Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease
Objective: To evaluate the association between Cannabidiol (CBD) usage and cognitive performance, measured by The Montreal Cognitive Assessment (MoCA) in people living with Parkinson's Disease…Therapeutic Effect and Mechanism of Targeted Nano-selenium in Mouse Model of Parkinson’s Disease Induced by MPTP
Objective: In the present study, we developed a nanozyme (Se@PB-ACPP) incorporating selenium-loaded Prussian blue (PB) and modified it with an activatable cell-penetrating peptide (ACPP) to…Prodromal Parkinson’s Disease in Agent Orange Exposed US Vietnam Veterans
Objective: 1-Comparing the risk of prodromal PD between AO exposed veterans (AOEV) and non-AO exposed veterans without PD (Controls) in a Veterans Affairs (VA) hospital…GCase and Ganglioside GM1 Interaction in Parkinson’s Disease
Objective: The project aims to further understand the role of the ganglioside GM1 in the relationship between GBA1 mutations and higher α-synuclein levels. Background: Among…PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA
Objective: To assess the effect of KM-819 on the progression of multiple system atrophy (MSA). Background: Parkinson’s brain is associated with increased expression of the…Neuroprotective efficacy of EDTA against manganese neurotoxicity: Implications for modulating Parkinsonian syndromes
Objective: This study investigates the neuroprotective potential of ethylenediaminetetraacetic acid (EDTA) in reducing the neurotoxic effects of manganese (Mn), focusing on both motor and non-motor…Targeted Brain Delivery of Rifampicin via PEG-PLA Nanoparticles: A Promising Therapeutic Strategy for Neuroprotection and Disease Modification in Parkinsonian Mouse Models
Objective: This study aimed to design and validate a nanoparticle-based delivery system for rifampicin, with the objective of enhancing its therapeutic efficacy, improving brain targeting,…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…Evaluation of Neuroprotective Effect of Terminalia macroptera on Rotenone Induced Parkinson’s Disease in Mice
Objective: This study investigates the neuroprotective effects of an aqueous extract of Terminalia macroptera (AETM) in a rotenone-induced Parkinsonism mouse model. Background: Parkinson’s disease (PD)…
- 1
- 2
- 3
- …
- 15
- Next Page »